<HashMap><database>GEO</database><file_versions><headers><Content-Type>application/xml</Content-Type></headers><body><files><Other>ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE343nnn/GSE343216/</Other></files><type>primary</type></body><statusCode>OK</statusCode><statusCodeValue>200</statusCodeValue></file_versions><scores/><additional><omics_type>Transcriptomics</omics_type><species>Mus musculus</species><gds_type>Expression profiling by high throughput sequencing</gds_type><full_dataset_link>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE343216</full_dataset_link><repository>GEO</repository><entry_type>GSE</entry_type></additional><is_claimable>false</is_claimable><name>The mesenchymal state of NF1-associated malignant peripheral nerve sheath tumor is vulnerable to synergistic p53-pathway activation by combined MEK and MDM2 inhibition</name><description>Malignant peripheral nerve sheath tumor (MPNST) is unique as a mesenchymal neoplasm/sarcoma arising from benign plexiform neurofibroma (PNF), a neuroepithelial-derived Schwann cell (SC) tumor associated with neurofibromatosis type 1 (NF1). Using genetically engineered mouse models, we show that Nf1 loss efficiently induced RAS-MEK-ERK/MAPK-driven PNFs from developmentally abnormal nonmyelinating SCs, but no SC/epithelial-to-mesenchymal transition (EMT) or MPNST. Additional loss of Cdkn2a or p53 was required for Nf1-deficient PNFs to progress into MPNSTs. Using a high-throughput drug-repurposing screen and p53-off/on switchable system, we uncovered that MEK inhibition (MEKi) reduced Mdm2/MDM2 expression and activated p53-mediated apoptosis, which was curbed by the p53-MDM2 negative feedback loop, but overcome by MDM2 inhibitors (MDM2i). Importantly, combined MEKi/MDM2i treatment eliminated MEKi- and MDM2i-induced resistant MPNSTs by synergistically activating p53-mediated MEKi-induced apoptosis and MDM2i-driven EMT reversal with SC differentiation. Thus, the mesenchymal state of MPNST is vulnerable to p53-pathway activation, providing a therapeutic strategy for this incurable cancer.</description><dates><publication>2026/09/01</publication></dates><accession>GSE343216</accession><cross_references><GSM>GSM9947893</GSM><GSM>GSM9947850</GSM><GSM>GSM9947894</GSM><GSM>GSM9947891</GSM><GSM>GSM9947892</GSM><GSM>GSM9947890</GSM><GSM>GSM9947857</GSM><GSM>GSM9947858</GSM><GSM>GSM9947899</GSM><GSM>GSM9947855</GSM><GSM>GSM9947856</GSM><GSM>GSM9947853</GSM><GSM>GSM9947897</GSM><GSM>GSM9947854</GSM><GSM>GSM9947898</GSM><GSM>GSM9947851</GSM><GSM>GSM9947895</GSM><GSM>GSM9947896</GSM><GSM>GSM9947852</GSM><GSM>GSM9947859</GSM><GSM>GSM9947860</GSM><GSM>GSM9947861</GSM><GSM>GSM9947868</GSM><GSM>GSM9947901</GSM><GSM>GSM9947902</GSM><GSM>GSM9947869</GSM><GSM>GSM9947866</GSM><GSM>GSM9947867</GSM><GSM>GSM9947900</GSM><GSM>GSM9947864</GSM><GSM>GSM9947865</GSM><GSM>GSM9947862</GSM><GSM>GSM9947863</GSM><GSM>GSM9947909</GSM><GSM>GSM9947907</GSM><GSM>GSM9947908</GSM><GSM>GSM9947905</GSM><GSM>GSM9947906</GSM><GSM>GSM9947903</GSM><GSM>GSM9947904</GSM><GSM>GSM9947871</GSM><GSM>GSM9947872</GSM><GSM>GSM9947870</GSM><GSM>GSM9947879</GSM><GSM>GSM9947912</GSM><GSM>GSM9947913</GSM><GSM>GSM9947910</GSM><GSM>GSM9947877</GSM><GSM>GSM9947911</GSM><GSM>GSM9947878</GSM><GSM>GSM9947875</GSM><GSM>GSM9947876</GSM><GSM>GSM9947873</GSM><GSM>GSM9947874</GSM><GSM>GSM9947882</GSM><GSM>GSM9947883</GSM><GSM>GSM9947880</GSM><GSM>GSM9947881</GSM><GSM>GSM9947888</GSM><GSM>GSM9947889</GSM><GSM>GSM9947886</GSM><GSM>GSM9947887</GSM><GSM>GSM9947884</GSM><GSM>GSM9947885</GSM><GPL>24247</GPL><GSE>343216</GSE><taxon>Mus musculus</taxon></cross_references></HashMap>